SecBot SecBot

QNCX

IRulya Therapeutics Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. CA· CIK 0001662774 Biotech & Drug Discovery
$32.47 +1.09 (+3.49%)
Oct 27 4:00 PM ET · prev $31.38
Market cap
$29.9M
Nano cap
Consensus
Buy
92% Buy or better · 13 analysts
Median target
$71.00
+119% · range $65.00–98.00
Since first trade
+72.0%
from $18.88 · Jul 17
30 days
+12.0%
from $29.00
Range since listing
$17.85–40.27
−19% from high · low Jul 27
Avg volume 20D
77.7K
Oct 20 spike 317.1K
Short interest
59.9K
≈5.9% of shares · +19.2%
Days to cover
2.7
at average volume
Insider net
$0
no open-market trades · 12 mo
Filing reports
12
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 2 bearish · 2 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 8/8
Strongest BULLISH Quince Therapeutics has completed its transformation into IRulya Therapeutics, executing a full leadership…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • AnalystsBULLISH

    12 of 13 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$8.800 → −$1.200 over 90 days.

  • Short sellersBUILDING

    Short interest +19.2% to 59.9K shares. 2.7 days to cover, ≈5.9% of shares.

  • TrendUPTREND

    4% above its 50-day average.

Who's buying

13F
Top holderSharesValue
TUDOR INVESTMENT CORP ET AL220,000$22.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

13 analysts
Buy 92% rate it Buy or better
Strong Buy4Buy8Hold1Sell0Strong Sell0
12-month targets · 8 analysts

Price is below the lowest target. Median implies +119%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Oct 9, 2026Raymond James
INITIATE
INITIATEOutperform
Sep 24, 2026Rodman & Renshaw
INITIATE
INITIATEBuy
Sep 22, 2026Citizens
UPGRADE
UPGRADEMarket Outperform
Aug 18, 2026Cantor Fitzgerald
REITERATE
REITERATEOverweight
Jul 29, 2026Oppenheimer
INITIATE
INITIATEOutperform
Jun 24, 2026Leerink Partners
INITIATE
INITIATEOutperform

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 11, 2026
Lamond David
Director
AWARD2,700 sh
Jun 11, 2026
Senner Christopher J.
Director
AWARD2,700 sh
May 18, 2026
Roberts Brigette
Chief Corp. Affairs Officer
AWARD34,675 sh
May 18, 2026
Roberts Brigette
Chief Corp. Affairs Officer
AWARD228,855 sh
May 18, 2026
Roberts Brigette
Chief Corp. Affairs Officer
AWARD124,830 sh
May 18, 2026
Roberts Brigette
Chief Corp. Affairs Officer
AWARD69,350 sh
May 18, 2026
Roberts Brigette
Chief Corp. Affairs Officer
AWARD362,092 sh
May 18, 2026
Roberts Brigette
Chief Corp. Affairs Officer
AWARD133,615 sh

Earnings setup

Estimates
−$1.20
EPS estimate, this quarter
+86%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.20-$1.40–-$0.83-9.1%$0.00
Next Q-$1.11-$1.60–-$0.71-28.3%$0.00
Current FY-$3.65-$8.00–-$0.96+0.0%$0.00
Next FY-$4.68-$6.60–-$3.49+0.0%$0.00

Short side

FINRA· Sep 30, 2026
59,944
shares short
+19.2%
vs prior settlement
2.7
days to cover
≈5.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 12, 2026 Listing status
Delisted: QNCX — removed from the Nasdaq symbol directory
Quince Therapeutics, Inc. - Common Stock
Oct 9, 2026 SEC
Quince Therapeutics has completed its transformation into IRulya Therapeutics, executing a full leadership overhaul…
8-K — Impact 7/10
Oct 2, 2026 SEC
Quince Therapeutics filed a DEFA14A supplement to its proxy statement, announcing that three directors (June Bray…
DEFA14A — Impact 5/10
Oct 2, 2026 SEC
Three directors (June Bray, David Lamond, Christopher Senner) tendered conditional resignations effective after the…
8-K — Impact 3/10
Jun 11, 2026 Insider
Lamond David was granted 2,700 shares
Director
Jun 11, 2026 Insider
Senner Christopher J. was granted 2,700 shares
Director
May 18, 2026 Insider
Roberts Brigette was granted 34,675 shares
Chief Corp. Affairs Officer
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 12, 2026
Listing
Delisted: QNCX — removed from the Nasdaq symbol directory
Quince Therapeutics, Inc. - Common Stock
Sep 8, 2026
Listing
Listing Status: QNCX — Deficient (was Normal)
Quince Therapeutics, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
Sep 3, 2026
Press release
Quince Therapeutics to Participate in September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company…
Aug 14, 2026
Earnings
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved…
Aug 10, 2026
Earnings date
QNCX Q2 2026 Earnings Scheduled — 2026-08-10

SecBot reports

12 filings · 2 bullish · 2 bearish · 1 mixed · 7 neutral
All QNCX filing & press-release reports (12)